A gatekeeper point mutation, involving the substitution of threonine with isoleucine at position 315 (T315I) in the BCR–ABL protein, was identified in CML patients resistant to imatinib in 2001.52 Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.